Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas.

Press Release - BioSnate Pharmaceuticals, Inc. (BPAX-NASDAQ)

BioSante is a product development company. From the beginning, we have had our eye on women’s sexual health. Right now, we are developing a product, LibiGel®, for the treatment of female sexual dysfunction for which there is no product approved in the United States. We believe this represents a blockbuster opportunity. - Stephen M. Simes (BPAX) (Interview published March 11, 2011)

The Most Powerful Name In Corporate News and Information.


Members Login

Become A Member!


BioSante Pharmaceuticals, Inc. To Present

at Cancer Immunotherapy Conference

LINCOLNSHIRE, Illinois (October 3, 2011) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Cancer Immunotherapy: A Long Awaited Reality conference taking place on October 6, 2011, at the New York Academy of Medicine in New York. The single-day conference event unites key opinion leaders, industry executives, and other stakeholders to engage in discussions, exchange information, and highlight opportunities in the field of cancer immunotherapy.

Stephen M. Simes, BioSante's president & chief executive officer, will speak at 1:45 pm EDT, and will provide an overview of BioSante's portfolio of cancer vaccines currently in multiple Phase II clinical trials.

The conference will be hosted by MD Becker Partners and sponsored by JMP Securities, Thompson Hine, Roth Capital Partners and Cantor Fitzgerald. There will be a corresponding live webcast of the presentations, which can be accessed by visiting www.regonline.com/mdbpartners. A replay will be available for 30 days.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin (estradiol gel), indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel , a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at: www.biosantepharma.com.


About MD Becker Partners

MD Becker Partners LLC is a boutique management and strategy consulting firm focusing on both public and private companies in the life science industry. As a strategic advisor and partner, the firm provides a full range of services to help clients increase visibility, unlock stakeholder value and access resources to grow their business. To accomplish this, MD Becker Partners integrates relations, strategy, and operational capabilities and applies them to carefully conceived and expertly enacted tactics. For more information visit www.mdbpartners.com.


For more information, please contact:

For Media:

Harris D. McKinney, Inc.

Alan Zachary

email: azachary@mckinneychicago.com

phone: (312) 506-5220

For Investors:

The Trout Group LLC

Tricia Swanson

E-Mail: tswanson@troutgroup.com

Phone: (646) 378-2953


ceocfointerviews.com does not purchase or make
recommendation on stocks based on the interviews published.